I agree. I believe that with the vast amount of data that has been obtained in this DCVax-L Phase 3 trial, and because of its safety profile, NWBio will be able to get additional approvals for other operable solid tumor cancers in a much shorter period of time, using surrogate endpoints.
The FDA & the other RAs will probably require NWBio to conduct ongoing confirmatory trials to continue to track patients' Overall Survival (OS) over 3, 5, 7, years and further.
Market Data 
Markets 
